Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2005

View Archived Issues

Promising results reported for the purgative INKP-102 in colonoscopy patients

First phase I data on the effects and safety of the HIV vaccine tgAAC-09

J&J synthesizes H3 receptor antagonist with wake-promoting effects in rats

First HERG channel activator discovered

Somaxon licenses rights for oral nalmefene for nicotine dependence

Dalbavancin NDA granted priority review

Prolexys licenses novel anticancer compounds

Corgentech to discuss registration strategy for edifoligide with FDA

Medarex to receive milestone for antibody advancement

Genzyme initiates phase II gene transfer study in peripheral arterial disease

Pfizer to acquire Idun Pharmaceuticals

DOV-102677 enters phase I

Copaxone evaluated in combination with NAC for relapsing remitting MS

UIC-02031 blocks replication of primary and multidrug-resistant HIV variants

TAK-652 shows potent in vitro anti-HIV-1 activity and a safe profile in humans

Pegasys receives FDA approval for HIV-HCV coinfected patients

First phase I data on the effects of GPI-0100 in prostate cancer

TH-9507 improves quality of life of HIV-infected patients with abdominal fat accumulation

L-000870810 reported to reduce viral load in HIV-infected patients

PRO-2000/5 gel retains antiviral efficacy for up to one hour after intravaginal application

Update on the antiretroviral efficacy of TMC-278 in HIV infection

Therapeutic benefits of rFVIIa in patients with acute intracerebral hemorrhage

Novel DPP-IV inhibitors for type 2 diabetes reported by Merck

New PPARdelta/PPARalpha agonists disclosed by Roche

Vertex presents ABC transporter modulators for use in cystic fibrosis therapy

Anti-human papillomavirus (HPV) agents claimed by GSK

Novel MMP inhibitors discovered by GlaxoSmithKline

New inhibitors of MHC class I expression described by Nippon Kayaku scientists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...